Davidson Investment Advisors Has $21.71 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 27th, 2023

Davidson Investment Advisors reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 122,893 shares of the company’s stock after selling 1,633 shares during the quarter. Johnson & Johnson accounts for 1.7% of Davidson Investment Advisors’ holdings, making the stock its 12th biggest holding. Davidson Investment Advisors’ holdings in Johnson & Johnson were worth $21,709,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. DORCHESTER WEALTH MANAGEMENT Co lifted its holdings in shares of Johnson & Johnson by 8.6% during the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after acquiring an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P lifted its stake in Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after purchasing an additional 82,429 shares during the last quarter. AMI Investment Management Inc. boosted its holdings in shares of Johnson & Johnson by 8.8% in the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after purchasing an additional 1,475 shares in the last quarter. Equitable Holdings Inc. increased its stake in shares of Johnson & Johnson by 4.9% in the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after purchasing an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd lifted its position in shares of Johnson & Johnson by 2.4% during the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after buying an additional 20,528 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $162.62 on Thursday. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $184.82. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. The business has a 50-day moving average price of $157.64 and a two-hundred day moving average price of $167.00. The company has a market cap of $423.51 billion, a P/E ratio of 34.02, a PEG ratio of 2.79 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The company had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. During the same quarter in the previous year, the business posted $2.67 EPS. Johnson & Johnson’s revenue for the quarter was up 5.6% compared to the same quarter last year. As a group, analysts anticipate that Johnson & Johnson will post 10.67 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a yield of 2.93%. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is 94.56%.

Insiders Place Their Bets

In other news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on JNJ. Piper Sandler decreased their target price on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Raymond James decreased their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 19th. Morgan Stanley increased their price target on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 19th. Finally, Atlantic Securities reduced their price objective on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $173.00.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.